These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37186942)

  • 21. [Antibody alternative formats: antibody fragments and new frameworks].
    Kitten O; Martineau P
    Med Sci (Paris); 2019 Dec; 35(12):1092-1097. PubMed ID: 31903922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homogeneously modified immunoglobulin domains for therapeutic application.
    Liu T; Du J; Luo X; Schultz PG; Wang F
    Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody drug conjugates.
    Teicher BA
    Curr Opin Oncol; 2014 Sep; 26(5):476-83. PubMed ID: 25024051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates.
    Sharkey RM; Sausville EA; Goldenberg DM
    Cancer Res; 2003 Nov; 63(22):8069-71. PubMed ID: 14633741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical Biology Approaches toward Precise Structure Control of IgG-Based Antibody-Oligonucleotide Conjugates.
    Shen L; Wu Y; Xie W; Chen G; Xing H
    Chembiochem; 2023 May; 24(9):e202300077. PubMed ID: 36892014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.
    Umotoy JC; de Taeye SW
    Front Immunol; 2021; 12():708806. PubMed ID: 34276704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles.
    Petrilli R; Pinheiro DP; de Cássia Evangelista de Oliveira F; Galvão GF; Marques LGA; Lopez RFV; Pessoa C; Eloy JO
    Curr Med Chem; 2021; 28(13):2485-2520. PubMed ID: 32484100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status.
    Bhatt P; Vhora I; Patil S; Amrutiya J; Bhattacharya C; Misra A; Mashru R
    J Control Release; 2016 Mar; 226():148-67. PubMed ID: 26860284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of potential antibody-based therapies for myeloma.
    Sherbenou DW; Behrens CR; Su Y; Wolf JL; Martin TG; Liu B
    Blood Rev; 2015 Mar; 29(2):81-91. PubMed ID: 25294123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?
    Esteva FJ; Miller KD; Teicher BA
    Am Soc Clin Oncol Educ Book; 2015; ():e117-25. PubMed ID: 25993162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the treatment of hematologic malignancies using immunoconjugates.
    Palanca-Wessels MC; Press OW
    Blood; 2014 Apr; 123(15):2293-301. PubMed ID: 24578502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The state-of-play and future of antibody therapeutics.
    Elgundi Z; Reslan M; Cruz E; Sifniotis V; Kayser V
    Adv Drug Deliv Rev; 2017 Dec; 122():2-19. PubMed ID: 27916504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment.
    Zhuang C; Guan X; Ma H; Cong H; Zhang W; Miao Z
    Eur J Med Chem; 2019 Feb; 163():883-895. PubMed ID: 30580240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives.
    Zangemeister-Wittke U
    Pathobiology; 2005; 72(6):279-86. PubMed ID: 16582579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [An overview of antibody-based cancer therapy].
    Miao QF; Shao RG; Zhen YS
    Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
    Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
    J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies: nanoconjugates for protection against endothelial oxidative stress.
    Shuvaev VV; Dziubla T; Wiewrodt R; Muzykantov VR
    Methods Mol Biol; 2004; 283():3-19. PubMed ID: 15197299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.